Table 2 Healthcare personnel feedback on the operational processes of the ototoxicity monitoring programme

1. How many patients with cervical cancer did you treat/dispense cisplatin medication to, during the study period?

 < 20

0

1 (12.5)

4 (44.4)

0

20–50

2 (33.3)

2 (25.0)

2 (22.2)

1 (11.1)

50–70

1 (16.7)

0

3 (33.3)

0

70–100

3 (50.0)

5 (62.5)

0

8 (88.9)

2. Did you notice any changes in the patient’s hearing?

No

2 (33.3)

3(37.5)

9 (100)

7 (77.8)

Yes

1 (16.7)

1(12.5)

0(0)

1 (11.1)

Sometimes

3 (50.0)

4 (50.0)

0(0)

1 (11.1)

3. Do you provide patients with information regarding the ototoxic effects of medication?

No

1 (16.7)

2 (25)

9(42.9)

7(77.8)

Yes

4(66.7)

6 (75)

0(0)

1(11.1)

Sometimes

1 (16.7)

0 (0)

0(0)

1(11.1)

4. Do you provide patients with any information regarding their hearing?

No

1 (16.7)

2 (25.0)

9 (100.0)

7 (77.8)

Yes

2 (33.3)

3 (37.5)

0 (0)

1 (11.1)

Sometimes

3 (50.0)

3 (37.5)

0 (0)

1 (11.1)

5. Do you enquire about patient’s history of hearing difficulties?

No

0 (0)

3 (37.5)

9 (100)

6 (66.7)

Yes

1 (16.7)

1(12.5)

0 (0)

1 (11.1)

Sometimes

5 (83.3)

4 (50.0)

0 (0)

2 (22.2)

6. How many referrals have you made to the audiologist over the last year?

 < 20

6 (100.0)

6 (75.0)

9 (100.0)

9 (100.0)

20–50

0 (0)

1 (12.5)

0 (0)

0 (0)

51–70

0 (0)

1 (12.5)

0 (0)

0 (0)

7. Do you feel that the ototoxicity monitoring program is beneficial?

No

0 (0.0)

0 (0.0)

2 (22.2)

1 (11.1)

Yes

6 (100.0)

8 (100.0)

7 (77.8)

8 (88.9)

8. Was the team approach to managing the patient with cervical cancer successful?

No

1 (16.7)

0 (0)

7 (77.8)

1 (11.1)

Yes

2 (33.3)

6 (75.0)

0 (0.0)

3 (33.3)

Sometimes

3 (50.0)

2 (25.0)

2 (22.3)

5 (55.6)